In a large kindred of66 individuals, 22 were identified as heterozygous and 3 as homozygous for a mutation (pro,4 -o leu) in the LDL-receptor gene that gives rise to familial hypercholesterolaemia (FH). All the heterozygotes had a raised level of plasma total cholesterol and low density lipoprotein cholesterol, but were remarkably free from premature coronary disease. Determination of apolipoprotein(a) (apo(a)) phenotype and lipoprotein(a) (Lp(a)) concentration in plasma revealed that in many instances, involving individuals with various apo(a) phenotypes, there was no difference in plasma Lp(a) concentration between an FH heterozygote and an unaffected sibling with the same apo(a) phenotype. No significant difference in Lp(a) concentration was observed between groups of FH and non-FH of the same apo(a) phenotype, although in each case the mean value for the FH group was greater than that for the non-FH group. There was also evidence for an inherited trait that markedly increased Lp(a) concentration, which did not segregate with apo(a) phenotype or the defective LDL-receptor allele. The data provide no evidence for a strong multiplicative interaction between the gene loci for apo(a) and the LDL receptor. (J. Clin. Invest. 1991. 88:483-492.)
Introduction
Familial hypercholesterolaemia (FH)l is an inherited disorder in which a mutation in the gene for the LDL receptor results in defective catabolism of plasma LDL (1) . Approximately 1 in 400 persons in most populations carries one defective gene for the LDL receptor, but homozygotes, who are much more se- 1 . Abbreviations used in this paper: CHD, coronary heart disease; FH, familial hypercholesterolemia; HMG CoA, 3-hydroxy-3-methylglutaryl Coenzyme A; Lp(a), lipoprotein(a).
verely affected, are rare. The disorder is characterized by a marked increase in the plasma concentration of LDL and the presence of tendon xanthomata, and is often associated with a family history of premature coronary heart disease (CHD) (2) .
It has long been recognized that there is considerable variation in the severity of the symptoms amongst FH heterozygotes, but the molecular basis of this is not fully understood. One explanation undoubtedly lies in the diversity of defects in the LDL receptor gene, in that more than 20 different mutations have already been described while many more remain to be identified (3) .
Although LDL receptor gene defects can be broadly classified as "receptor-negative" or "receptor-defective" according to their effect on the function ofLDL receptors in cultured skin fibroblasts from FH patients (1), there is not always a strong correlation between residual receptor activity and the severity of the disease in the patient (Soutar, A. K., G. R. Thompson, and B. L. Knight, unpublished observations). It is not altogether surprising that other factors may be involved, because numerous genetic and environmental risk factors for CHD have been identified in the general population (4) . For example, a high concentration of lipoprotein(a) (Lp(a)) in plasma is associated with a considerable risk for development of premature CHD (5) , and it has recently been suggested that some, if not all, of the severity of CHD amongst FH heterozygotes depends on the plasma concentration of Lp(a) (6) . Lp(a) comprises an LDL-like lipoprotein particle to which another glycoprotein, apolipoprotein (apoXa), is tightly associated (7) . There is considerable inherited phenotypic variation in the apparent size of apo(a) between individuals (8, 9) and it has been found that, in a Tyrolean population, there is a strong association between apo(a) phenotype and the concentration of Lp(a) in plasma (9) . However, the mechanisms regulating Lp(a) metabolism are poorly understood and it has not yet been fully established what role the LDL receptor plays (10, 1 1). Data from a heterogeneous group of clinically diagnosed FH heterozygotes attending lipid clinics has shown that, within each apo(a) phenotype, the Lp(a) concentration in the plasma ofFH heterozygotes is, on average, threefold higher than normal (12) . This observation has led Utermann and colleagues to suggest that premature CHD in FH does not result from a single gene defect in the LDL receptor gene, but requires the interaction of at least two genes (6, 12) .
We have recently identified a mutation in the LDL receptor gene of an FH homozygote of Asian-Indian origin, in which substitution ofa proline residue at amino acid residue 664 with leucine (13) results in a receptor-defective phenotype. The precursor form of the mutant receptor is converted more slowly than normal and the mature form on the cell surface binds LDL less well than normal (14) .
The proband is a member of a large family in which there are several first cousin marriages in each generation that has resulted in four homozygotes and numerous heterozygotes in the kindred. We now report our findings on the effect of this mutation in the LDL receptor gene on the concentration of plasma lipids and lipoproteins; in particular, we have focussed on the possible relationship between LDL receptor function, apo(a) phenotype and the concentration of Lp(a) in plasma.
Methods
Subjects. Blood samples were obtained from 66 members ofthe family now resident in the UK or visiting from Zambia. The family is Muslim and originates from Gujerat in the west coast area of India, they had maintained their traditional, nonvegetarian diet, and none were smokers. Each member ofthe family was assigned a number. A history for symptoms of CHD and drug treatment was obtained, and the presence of tendon xanthomata was noted. There was no opportunity for investigation of CHD in asymptomatic subjects. Only numbers 1 and 23 had symptomatic CHD; both were being treated with an inhibitor of 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase, a 3-blocker and a vasodilator; number 27 was also treated with an inhibitor of HMG-CoA reductase. Two of the three homozygous FH subjects were treated with two-weekly plasma exchange (numbers 16 and 42); number 42 was also treated with probucol. The third homozygote (number 56) had been offtreatment for 1 mo due to a suspected gastric ulcer, but had been treated with weekly plasma exchange and an HMG-CoA reductase inhibitor.
Venous blood was collected into tubes containing EDTA and imme- (-20 ,l), and stored frozen at -70°C until required. Thus, determinations of Lp(a), apo B, and apo AI concentrations or apo(a) phenotype were always performed on samples that had been frozen and thawed twice. There was no apparent difference between values obtained with fresh samples and with samples treated in this way.
Lp(a) concentration was assayed with a "Tint Elize Lp(a)" enzyme immunoassay kit (Biopool AB, Umea', Sweden) using the dilutions and procedures recommended by the manufacturer. The assay gave no signal with plasminogen at a concentration less than 1 mg/ml in the undiluted plasma. Samples that gave values close to or above that of the highest standard were reassayed with one-half ofthe normal volume of diluted sample in the reaction well. 10 samples assayed in this way gave plasma values that were the same (101.5±1.9%, mean±SE) as those obtained by the standard procedure.
The plasma apo B and apo Al concentrations were determined with commercially available kits, using the procedure recommended by the manufacturer (Boehringer Mannheim CBR-program; Mannheim, FRG).
Plasma lipid determinations were made within 1 wk of blood collection. Plasma that had been stored at 40C (5 ml) was centrifuged at d 1.006 g/ml for 16 h at 80C in a 50.3 rotor (Beckman Instrs., Inc., Fullerton, CA), and the VLDL fraction obtained by tube slicing. VLDL was stored frozen at -20'C for subsequent determination of apo E phenotype. Plasma HDL cholesterol was determined by assaying the concentration of cholesterol in the supernatant obtained after heparin-manganese precipitation (16) of the d > 1.006 g/ml fraction of plasma, while LDL cholesterol was determined as the difference between the cholesterol concentration in the d > 1.006 g/ml fraction and HDL cholesterol.
Because it was not possible to obtain fasting samples from all members of the family, fasting plasma triglyceride levels could not be determined.
Determination ofapo(a) and apo E phenotypes. Apo(a) phenotype was determined by procedures based on those described by Kraft et al. (17) . Samples of frozen plasma (25 Ml) were lyophilized and delipidated overnight with acetone-ethanol (1:1, vol/vol). The precipitates were washed once with diethyl ether, dried, and dissolved by boiling for 10 min with 50 ,l of sample buffer (2 ml of 5% SDS with 200 ,l of fl-mercaptoethanol and 300 ul of bromophenol blue in glycerol). Samples were centrifuged for 5 min in a Beckman microfuge and portions ofthe supernatant were subjected to discontinuous SDS-PAGE at room temperature according to the method of Laemmli (18) 
Results
Genomic DNA from each member of the family was analyzed for the presence of the prow4-. leu mutation in the LDL receptor gene by amplification and restriction enzyme digestion of a fragment comprising exons 13 and 14 together with short flanking sequences from introns on either side. The C T mutation introduces a PstI site in exon 14, so that the mutant 492-bp fragment is digested by this enzyme to give bands of 1 16 and 376 bp (Fig. 1) . Subjects in whom only the digested bands were observed were identified as homozygous for the mutant allele, while subjects in whom half the original 492-bp fragment remained after digestion were identified as heterozygotes. The LDL receptor genotypes of the subjects from whom a blood sample was analyzed are shown in the pedigree of this kindred in Fig. 2 members of the family (Fig. 3 ). There was a small but significant increase in LDL cholesterol concentration with increasing age in the non-FH members of the family, but not in the FH heterozygotes (Fig. 4) . The mean value for the concentration of HDL cholesterol and apo Al in plasma was lower in the FH heterozygotes than in the non-FH subjects, but the difference in mean HDL cholesterol concentration observed between non-FH males and females was not observed in the FH heterozygotes (Fig. 5) . The majority ofthe subjects were apo E phenotype E3/E3, although 11 subjects were apo E3/E4 and 1 was apo E2/E3 (see Appendix 1). The apo(a) phenotype of each subject was determined by identification ofbands, separated by SDS-gel electrophoresis of plasma, by immunoblotting with a specific antibody to Lp(a). Two clearly separate apo(a) bands were detected in samples from 52 of the 66 subjects, while only one band could be detected in the remaining 14 samples even when gels were loaded with as much Lp(a) as was consistent with maintaining sufficient resolution. From the pedigree, 10 of these could be deduced to be heterozygous for an apparently null allele, while the remaining 4 subjects could have been either homozygous for the single band or heterozygous for a null allele. As shown in Fig. 6 , the mobility ofthe apo(a) bands relative to that ofapo = 39), but not for the FH heterozygotes (r = 0.005, n = 22). The LDL cholesterol value for subject 7 (non-FH) who was in the third trimester of pregnancy, was omitted for determination of the correlation coefficient.
B fell into nine clearly defined groups each of which represented an apo(a) phenotypic band identified according to the median mobility of the group. Comparison with samples in which apo(a) phenotype had been determined by Utermann and colleagues (12) showed that phenotypes 42-51 correspond to S4, 61-65 to S3, 71 to S2, and 92 to S1. We have also identified nine other phenotypes ranging from 39 to 1 14 in plasma samples from the general population (Knight, B. L., Y. F. N. Perombelon, and A. K. Soutar, unpublished observations). In this kindred, apo(a) phenotype was apparently inherited according to a Mendelian mode of inheritance.
The concentration of Lp(a) in the plasma of the non-FH heterozygotes and FH homozygotes of each apo(a) phenotype is shown in Fig. 7 . The subjects are grouped according to the phenotypic apo(a) band ofhighest mobility which, in the majority ofcases, made the dominant contribution to plasma apo(a). The highest Lp(a) concentrations were seen in subjects with a phenotypic apo(a) band 92. Otherwise, there was no obvious association between Lp(a) concentration and apo(a) phenotype. This was most clearly demonstrated in subjects in whom there was an apparently null allele, where a single apo(a) phenotypic band determined the plasma concentration. The majority of the FH subjects were apo(a) phenotype 61 in combination with another slower migrating band, and it was only within this group that it was possible to make statistical comparisons between FH and normal subjects. As shown in Table I Within the groups shown in Table I in. which sufficient subjects were available to make a comparison, there was no apparent effect of increasing age on the plasma concentration of Lp(a), nor was there a significant difference between males and females.
The lack ofa direct effect ofthe LDL receptor defect on the plasma concentration of Lp(a) is clearly demonstrated by comparing siblings or parents and children in the branches of the family shown in Fig. 8 It is clear from the data shown in Fig. 7 and from the families shown in Fig. 8 In order to investigate this further, those members of the kindred in whom Lp(a) concentration was greater than the "expected" value for an individual with this apo(a) phenotype were identified. The "expected" value for an individual was calculated as twice the Lp(a) concentration ofa subject with an apparently null allele in combination with the dominant phenotypic band in the individual in question. Thus, for example, the "expected" value for an individual with apo(a) phenotype 61 in combination with another band of lower mobility would be twice that of an individual with apo(a) phenotype 61/N. All individuals with Lp(a) concentration greater than the expected value are marked with an asterisk (*) in the pedigree shown in Fig. 2 . The effect was observed in both normal and heterozygous FH individuals, and was not limited to any particular phenotype. In total, 12 of 40 non-FH, 13 of 22 FH heterozygotes, and 3 of 3 FH homozygotes were identified. In each case where a child had an anomalously high concentration ofLp(a) in plasma, the effect was seen in at least one parent, and where one or both parents had an anomalously high Lp(a) concentration, at least one of the children was also affected. Three families were identified in which neither parents nor children were affected. The effect was not restricted to blood relatives in that several ofthe spouses appeared to have anomalously high Lp may be hypertriglyceridemic. However, of the 14 potentially of66 individuals ofwhom one-third have inherited one normal hypertriglyceridemic subjects, only five had an anomalously and one defective allele for the LDL receptor. The defective high concentration of Lp(a) in plasma. Of these, two were FH allele was identified by gene amplification and has been dehomozygotes, one was a heterozygote, and two were non-FH.
scribed previously in several members of the kindred (13) . Three individuals who are homozygous for the defective LDL Discussion receptor allele were also identified, each a child of consanguinous marriage. Without exception, the heterozygous individuals In this study, the plasma lipid and lipoprotein concentrations had a raised plasma cholesterol concentration compared with have been determined in a large Muslim Asian-Indian kindred the unaffected relatives, and there was no suggestion of any Apo(a) phenotype was assigned on the basis of the relative mobility of apo(a) and apo B after fractionation of whole plasma by SDS-PAGE, as described in the legend to Fig. 6 . Subjects are grouped according to their apo(a) variant with greater electrophoretic mobility; for the majority, this was the dominant phenotypic apo(a) band. An apparently null phenotype is denoted as N. Single numbers denote phenotypes that could be either homozygous for the same phenotypic band or heterozygous for a null phenotype.
suppression of the expression of the defective allele in any of the family members as described recently in a Puerto Rican kindred with familial hypercholesterolemia (21) . However, the mean value for LDL cholesterol in the heterozygotes, the large majority of whom were receiving no lipid-lowering therapy, was 343.3±55 mg/dl and for the three homozygotes before treatment was 650±27.2 mg/dl; these values are at the lower end of the reported range for heterogeneous groups of FH heterozygotes and homozygotes (22) . Furthermore, although the mean values for HDL cholesterol and plasma apo Al were lower in the FH heterozygotes than in the unaffected individuals, they were not significantly so. These observations may in part explain the remarkable lack ofevidence ofpremature coronary heart disease in the affected individuals in this kindred. Of 22 heterozygotes with one defective LDL receptor allele, only two had symptomatic CHD and each was in the seventh decade of life. None of the heterozygotes identified by genotyping had clearly defined tendon xanthomata, although they were present in all three homozygotes. Thus, although one of the original objectives ofthis study was to determine whether there was any variation in the severity of CHD symptoms in FH heterozygotes with precisely the same inherited defect in the LDL receptor, this was clearly not possible.
The second objective of this study was to examine the relationship between FH and Lp(a) concentration, because it has recently been suggested that heterozygous FH patients have a plasma concentration of Lp(a) that is, on average, threefold that of normal individuals with the same apo(a) phenotype (12). We did not observe this phenomenon in the kindred described in this paper, despite the similar genetic background of many of the individuals due to consanguinous marriage. Indeed, in many instances it was possible to identify pairs of siblings ofthe same apo(a) phenotype, one heterozygous for the defective LDL receptor allele and the other apparently normal, in whom the plasma Lp(a) concentration was virtually identical.
For the kindred described in this paper, the classification of apo(a) phenotype that has been described previously (9) was not adequate to distinguish between subjects with clearly different phenotypic bands, and thus for this study we have classified apo(a) phenotype simply by measuring the relative electrophoretic mobility of the apo(a) bands. Because the values fell into discreet groups rather than as a continuous spectrum, we are confident that these represent different phenotypic bands. In a recent study, Gaubatz et al. (23) were able to detect one or two separate apo(a) bands in more than 99% of 692 samples assayed, and identified 11 different phenotypic bands. No significant difference in Lp(a) concentration between groups of FH and normal with the same apo(a) phenotype was observed, although the mean value for the FH heterozygotes was frequently greater than that of the non-FH individuals. In one family, an FH heterozygote and his FH homozygote daughter, each with apo(a) phenotype 51/48, there appeared to be a possible gene dosage relationship between the defective LDL receptor allele and plasma Lp(a) concentration. However, an unaf- (26) , and secondly, early studies on the turnover of Lp(a) in human subjects have suggested that Lp(a) concentration in plasma correlates strongly with its production rate but not with its fractional catabolic rate (27) . In a recent study, we also observed no difference in the fractional catabolic rate for Lp(a) between a group ofnormal and FH heterozygotes with matched apo(a) phenotype (28) .
One feature that emerged from the data in this paper was that some individuals in the kindred had an anomalously high Lp(a) concentration compared with the majority ofindividuals with that particular apo(a) phenotype, and there was some evidence that this could be an inherited trait. Although the trait was more common in FH individuals than in unaffected relatives, and was observed in all three homozygotes, it did not segregate in the pedigree with either the abnormal LDL receptor allele or with apo(a) phenotype. Because several of the nonblood relative spouses were also identified in this group it is possible that it is a relatively common trait, at least amongst this particular racial group. It would be ofinterest to carry out a similar study on other large kindreds with or without a defective LDL receptor allele. Because so little is known about the regulation of Lp(a) metabolism it is difficult to speculate about the nature of the mechanism operating to increase Lp(a) concentration in these individuals. Although apo(a) phenotype has been observed to have a strong influence on Lp(a) concentration in plasma, in a recent study Boerwinkle et al. (29) observed that it only amounts to -40% ofthe variance in Lp(a) concentration observed in a large population, suggesting that other genetic and environmental factors are also important. The significant risk of premature CHD associated with an increased concentration of Lp(a) in plasma and the resistance of Lp(a) concentration to reduction by drug treatment suggests that it is worthwhile to identify these factors. 
